|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 14.50 CAD | 0.00% |
|
-0.68% | +13.90% |
| 05-22 | BioSyent Inc., Q1 2026 Earnings Call, May 14, 2026 | |
| 05-19 | BioSyent Secures Health Canada Nod For Hypothyroidism Oral Solution | MT |
| Market Cap | 166M 118M 103M 95.47M 88M 11.4B 170M 1.14B 449M 5.58B 445M 435M 19.22B | P/E 2026 * |
16.3x | P/E 2027 * | 13.4x |
|---|---|---|---|---|---|
| Enterprise Value | 166M 118M 103M 95.47M 88M 11.4B 170M 1.14B 449M 5.58B 445M 435M 19.22B | EV / Sales 2026 * |
2.4x | EV / Sales 2027 * | 2.02x |
| Free-Float |
64.14% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: BioSyent Inc.
| 1 week | -0.68% | ||
| 1 month | +4.62% | ||
| 3 months | -2.03% | ||
| 6 months | +11.97% | ||
| Current year | +13.90% |
| 1 week | 14.5 |  | 14.65 |
| 1 month | 13.85 | | 14.72 |
| Current year | 12.25 | | 15.8 |
| 1 year | 10.65 | | 15.8 |
| 3 years | 7.41 | | 15.8 |
| 5 years | 6.24 | | 15.8 |
| 10 years | 3.13 | | 15.8 |
| Manager | Title | Age | Since |
|---|---|---|---|
René Goehrum
CEO | Chief Executive Officer | 66 | 1999-04-30 |
Robert March
DFI | Director of Finance/CFO | - | 2018-09-09 |
Navid Ashrafi
CTO | Chief Tech/Sci/R&D Officer | - | 2015-05-31 |
| Director | Title | Age | Since |
|---|---|---|---|
René Goehrum
CHM | Chairman | 66 | 1999-05-31 |
Peter Lockhard
BRD | Director/Board Member | 62 | 2002-05-31 |
Stephen Wilton
BRD | Director/Board Member | 65 | 2014-01-15 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 6/30/26 | Option | Director | -1,493 | 0.0131% | ||
| 6/30/26 | Option | Director | -689 | 0.0060% | ||
| 6/30/26 | Option | Executive/Senior Manager | -4,340 | 0.0379% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 0.00% | -0.68% | +27.19% | +93.08% | 118M | |
| +0.85% | -0.80% | +54.84% | +163.70% | 1,051B | |
| +1.23% | -1.53% | +55.26% | +59.07% | 609B | |
| +0.04% | +2.58% | +32.96% | +88.75% | 450B | |
| +0.78% | -0.71% | +30.04% | +24.61% | 330B | |
| +1.41% | +0.58% | +33.92% | +47.20% | 284B | |
| -0.27% | -1.87% | +22.13% | +23.47% | 263B | |
| -1.76% | +2.37% | -22.19% | -38.45% | 223B | |
| -1.42% | +0.80% | +22.81% | +60.77% | 198B | |
| -1.48% | +3.43% | +23.42% | +73.31% | 167B | |
| Average | -0.11% | +0.42% | +28.04% | +59.55% | 357.52B | |
| Weighted average by Cap. | +0.22% | +0.02% | +37.75% | +81.49% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 69M 49.25M 43.04M 39.72M 36.61M 4.74B 70.53M 475M 187M 2.32B 185M 181M 8B | 82.3M 58.74M 51.34M 47.37M 43.66M 5.66B 84.13M 566M 223M 2.77B 221M 216M 9.54B |
| Net income | - | - |
| Net Debt | - | - |
Employees
-
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-07-17 | $14.50 | 0.00% | 3,805 |
| 26-07-16 | $14.50 | -0.68% | 6,621 |
| 26-07-15 | $14.60 | 0.00% | 7,604 |
| 26-07-14 | $14.60 | +0.07% | 7,218 |
| 26-07-13 | $14.59 | -0.07% | 2,274 |
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
14.50CAD
Average target price
18.00CAD
Spread / Average Target
+24.14%
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- RX Stock
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
